GRI Stock Analysis: Buy, Sell, or Hold?
GRI - GRI Bio, Inc. Common Stock
$2.59
0.30 (13.10%)
▲
5d:
+34.9%
30d:
+67.1%
90d:
+29.5%
WAIT
LOW Confidence
Analysis Updated: Sep 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When GRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: GRI is 30.8% above its trading range ($1.98). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: GRI is 30.8% above its trading range ($1.98). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: GRI is currently trading at $2.59, which is considered extended relative to its 30-day fair value range of $1.49 to $1.98.
Technical Outlook: Technically, GRI is in a strong downtrend. The price is approaching resistance at $2.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.1% recently.
Market Sentiment: GRI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.50 (+707.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRI is in a strong downtrend. The price is approaching resistance at $2.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 13.1% recently.
Market Sentiment: GRI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.50 (+707.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.49 -
$1.98
Company Quality Score
29/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+30.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: Strong upward momentum (+13.1%)
- BULLISH: Trading 707.9% below Wall St target ($18.50)
- WARNING: Composite score 29/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.49 -
$1.98
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.65
Resistance Level
$2.50
Current Trend
Strong Downtrend
Technical data as of
Sep 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.13
Wall Street Target
$18.50
(+707.9%)
Share & Embed Analysis
Last updated: September 04, 2026 11:40 AM ET
Data refreshes hourly during market hours. Next update: 12:40 PM
Data refreshes hourly during market hours. Next update: 12:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 48 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 48 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 50 HOLD |
